ASH 2024: Polycythemia Vera and Myelofibrosis: Current and Future Standards of Care - Episode 14

Real-World Data in Myelofibrosis: Bridging the Gap Between Clinical Trials and Practice

, , , ,

Panelists discuss the types of questions that real-world (RW) data can answer in comparison to with clinical trial data, and how it they can complement clinical findings in treatment decision-making.

EP. 1: Initial Treatment Strategies for Polycythemia Vera
EP. 2: Cytoreductive Therapy in PV Treatment Paradigm
EP. 3: JAK Inhibition in Polycythemia Vera: Treatment Updates
EP. 4: Interferon Therapy in PV
EP. 5: Safety Considerations for PV Therapy
EP. 6: Evolving Treatment Strategies in Polycythemia Vera: Insights Ffrom Trials and Real-World Evidence
EP. 7: Interferon Real- World Treatment Patterns in PV
EP. 8: Considerations for Polycythemia Vera Management: Patient Monitoring, Outcomes, and Risks
EP. 9: Future Considerations for Polycythemia Vera Management: Takeaways from ASH 2024
EP. 10: An Overview to Myelofibrosis and Disease Risk
EP. 11: Treatment Goals for Myelofibrosis
EP. 12: Personalizing Therapy in Myelofibrosis: Insights from Key Clinical Trials
EP. 13: Advancing Myelofibrosis Treatment: Personalized Strategies with Fedratinib and Ruxolitinib
Now Viewing
EP. 14: Real-World Data in Myelofibrosis: Bridging the Gap Between Clinical Trials and Practice

Video content above is prompted by the following:

In comparison with clinical data, what questions can RW data answer?